Crossmark

A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies

Crossref DOI link: https://doi.org/10.1039/C9LC00925F

Published Online: 2020

Update policy: https://doi.org/10.1039/rsc_crossmark_policy

Authors

Phillips, Jonathan A. https://orcid.org/0000-0001-7290-754X
Grandhi, Taraka Sai Pavan

Davis, Myrtle

Gautier, Jean-Charles

Hariparsad, Niresh

Keller, Douglas https://orcid.org/0000-0002-6186-2881
Sura, Radhakrishna

Van Vleet, Terry R.
License Information

Accepted Manuscript valid from 2021-01-22
More Information

SIMILARITY CHECK

: This document is Similarity Check deposited

IDENTIFIERS

: Jonathan A. Phillips (ORCID)

: Douglas Keller (ORCID)

PEER REVIEW METHOD

: Single-blind

PUBLICATION HISTORY

: Received 17 September 2019; Accepted 12 January 2020; Accepted Manuscript published 22 January 2020; Advance Article published 28 January 2020; Version of Record published 4 February 2020